Mechanisms of lead-induced hypertension and cardiovascular disease

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 2, 2008, Pages

  Vaziri, Nosratola D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenergic system; Angiogenesis; Atherosclerosis; Catecholamines; Endothelial cell; Endothelial dysfunction; Endothelin; Heart; Heparan sulfate proteoglycans; Nitric oxide; Oxidative stress; Renin angiotensin aldosterone system; Thrombosis; Vascular smooth muscle

Indexed keywords

ENDOTHELIN; LEAD; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN DERIVATIVE; PROTEOGLYCAN; TISSUE PLASMINOGEN ACTIVATOR; HORMONE;

ADRENERGIC ACTIVITY; ANGIOGENESIS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENVIRONMENTAL EXPOSURE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LONG TERM EXPOSURE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; BLOOD CLOTTING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; PATHOPHYSIOLOGY; POLLUTANT; VASOCONSTRICTION;

ANIMALS; ATHEROSCLEROSIS; BLOOD COAGULATION; CALCIUM SIGNALING; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ENVIRONMENTAL POLLUTANTS; ENZYME ACTIVATION; HORMONES; HUMANS; HYPERTENSION; LEAD; VASOCONSTRICTION; VASODILATION;

EID: 52449099588     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00158.2008     Document Type: Review

References (97)

1. Attri J, Dhawan V, Mahmood S, Pandhi P, Parwana HK, Nath R. Effect of vitamin C supplementation on oxidative DNA damage in an experimental model of lead-induced HTN. Ann Nutr Metab 47: 294-301, 2003.
2. Bravo J, Quiroz Y, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and HTN in lead-exposed rats chronically. Am J Physiol Renal Physiol 293: F616-F623, 2007.
3. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840-844, 2000.
4. Campese V, Sindhu RK, Ye S, Vaziri ND, Jabbari B. Regional expression of NO synthase, NAD(P)H oxidase and superoxide dismutase in the rat brain. Brain Res 1134: 27-32, 2007.
5. Cardenas A, Roels H, Bernard AM, Barbon R, Buchet JP, Lauwerys RR, Rosello J, Ramis I, Mutti A, Franchini I. Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. Br J Ind Med 50: 28-36, 1993.
6. Carmignani M, Boscolo P, Poma A, Volpe AR. Kininergic system and arterial HTN following chronic exposure to inorganic lead. Immunopharmacology 44: 105-110, 1999.
7. Carmignani M, Volpe AR, Boscolo P, Qiao N, DiGioacchino M, Grill A, Felaco M. Catecholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci 68: 401-415, 2000.
8. Carsia RV, Forman D, Hock CE, Nagele RG, McIlroy PJ. Lead alters growth and reduces angiotensin II receptor density of rat aortic smooth muscle cells. Proc Soc Exp Biol Med 210: 180-190, 1995.
9. Chai S, Webb RC. Effects of lead on vascular reactivity. Environ Health Perspect 78: 85-89, 1988.
10. 2-adrenergic receptors and plasma catecholamine levels in lead-exposed workers. Toxicol Appl Pharmacol 1 39: 1-5, 1996.
11. Chang HR, Chen SS, Tsao DA, Cheng JT, Ho CK, Yu HS. Change of cardiac β-adrenoceptors in lead-exposed rats. Toxicology 123: 27-32, 1997.
12. Chang HR, Tsao DA, Yu HS, Ho CK. The change of β-adrenergic system after cessation of lead exposure. Toxicology 207: 73-80, 2005.
13. Cheng YJ, Schwartz PS, Vokonas Weiss A ST, Hu A, Hu H. Electrocardiographic conduction disturbances in association with low-level lead exposure (The Normative Aging Study). Am J Cardiol 82: 594-599, 1998.
14. Courtois E, Marques M, Barrientos A, Casado S, López- Farré A. Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. J Am Soc Nephrol 14: 1464-1470, 2003.
15. Ding Y, Gonick HC, Vaziri ND. Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am J Hypertens 13: 552-555, 2000.
16. Ding Y, Gonick HC, Vaziri ND, Liang K, Wei L. Lead-induced HTN. III. Increased hydroxyl radical production. Am J Hypertens 14: 169-173, 2001.
17. Ding Y, Vaziri ND, Gonick HC. Lead-induced HTN. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside. Environ Res 76: 107-113, 1998.
18. Dorman RV, Freeman EJ. Lead-dependent effects on arachidonic acid accumulation and the proliferation of vascular smooth muscle. J Biochem Mol Toxicol 16: 245-253, 2002.
19. Dursun N, Arifoglu C, Süer C, Keskinol L. Blood pressure relationship to nitric oxide, lipid peroxidation, renal function, and renal blood flow in rats exposed to low lead levels. Biol Trace Elem Res 104: 141-150, 2005.
20. Farmand F, Ehdale A, Roberts CK, Sindhu RK. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environ Res 98: 33-39, 2005.
21. Favalli L, Chiari MC, Piccinini F, Rozza A. Experimental investigations on the contraction induced by lead in arterial smooth muscle. Acta Pharmacol Toxicol 41: 412-420, 1977.
22. Fischbein A. Occupational and environmental exposure to lead. In: Environmental and Occupational Medicine, edited by Rom WN. Philadelphia: Lippincott-Raven, 1998, p. 973.
23. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708-1714, 2006.
24. Fujiwara Y, Kaji T. Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis. Toxicology 133: 147-157, 1999.
25. Fujiwara Y, Kaji T, Yamamoto C, Sakamoto M, Kozuka H. Stimulatory effect of lead on the proliferation of cultured vascular smooth-muscle cells. Toxicology 98: 105-110, 1995.
26. Fujiwara Y, Watanabe S, Sakamoto M, Kaji T. Repair of wounded monolayers of cultured vascular endothelial cells after simultaneous exposure to lead and zinc. Toxicol Lett 94: 181-188, 1998.
27. Giridhar J, Isom GE. Interaction of lead acetate with atrial natriuretic factor in rats. Life Sci 46: 569-576, 1990.
28. Goldstein GW. Evidence that lead acts as a calcium substitute in second messenger metabolism. Neurotoxicology 14: 97-101, 1993.
29. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND. Lead-induced HTN: interplay of nitric oxide and reactive oxygen species. Hypertension 30: 1487-1492, 1997.
30. Gonick HC, Ding Y, Vaziri ND. Effect of low lead exposure on eicosanoid excretion in rats. Prostaglandins Other Lipid Mediators 55: 77-82, 1998.
31. 2+ in calmodulin. Arch Toxicol 54: 61-70, 1983.
32. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695, 2005.
33. Hertz-Picciotto I, Croft J. Review of the relation between blood lead and blood pressure. Epidemiol Rev 15: 352-373, 1993.
34. Hotter G, Fels LM, Closa D, Roselló J, Stolte H, Gelpí E. Altered levels of urinary prostanoids in lead-exposed workers. Toxicol Lett 77: 309-312, 1995.
35. Hryhorczuk DO, Rabinowitz MB, Hessl SM, Hoffman D, Hogan MM, Mallin K, Finch H, Orris P, Berman E. Elimination kinetics of blood lead in workers with chronic lead intoxication. Am J Ind Med 8: 33-42, 1985.
36. Hwang KY, Lee BK, Bressler JP, Bolla KI, Stewart WF, Schwartz BS. Protein kinase C activity and the relations between blood lead and neurobehavioral function in lead workers. Environ Health Perspect 110: 133-138, 2002.
37. Kaji T, Fujiwara Y, Hoshino M, Yamamoto C, Sakamoto M, Kozuka H. Inhibitory effect of lead on the proliferation of cultured vascular endothelial cells. Toxicology 95: 87-92, 1995.
38. Kaji T, Ohkawara S, Nakajima M, Yamamoto C, Fujiwara Y, Miyajima S, Koizumi F. Lead-induced alteration of heparan sulfate proteoglycans in cultured vascular endothelial cells. Toxicology 118: 1-10, 1997.
39. Kaji T, Suzuki M, Yamamoto C, Mishima A, Sakamoto M, Kozuka H. Severe damage of cultured vascular endothelial cell monolayer after simultaneous exposure to cadmium and lead. Arch Environ Contam Toxicol 28: 168-172, 1995.
40. Kaji T, Yamamoto C, Sakamoto M. Effect of lead on the glycosaminoglycans metabolism of bovine aortic endothelial cells in culture. Toxicology 68: 249-257, 1991.
41. Kaji T, Yamamoto C, Sakamoto M, Kozuka H. Inhibitory effect of lead on the release of tissue plasminogen activator from human vascular endothelial cells in culture. Toxicology 73: 219-227, 1992.
42. Khalil-Manesh F, Gonick HC, Weiler EWJ, Prins B, Weber MA, Purdy RE. Lead-induced HTN: possible role of endothelial factors. Am J Hypertens 6: 723-729, 1993.
43. Khalil-Manesh F, Gonick HC, Weiler EWJ, Prins B, Weber MA, Purdy RE, Ren Q. Effect of chelation treatment with dimercaptosuccinic acid (DMSA) on lead-related blood-pressure changes. Environ Res 65: 86-99, 1994.
44. Kishimoto T, Oguri T, Ueda D, Tada M. Effect of lead on tube formation by cultured human vascular endothelial cells. Arch Toxicol 69: 718-721, 1995.
45. Lai CC, Lin HH, Chen CW, Chen SH, Chiu TH. Excitatory action of lead on rat sympathetic preganglionic neurons in vitro and in vivo. Life Sci 71: 1035-1045, 2002.
46. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
47. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med 162: 2443-2449, 2002.
48. Malvezzi CK, Moreira EG, Vassilieff I, Vassilieff VS, Cordellini S. Effect of L-arginine, dimercaptosuccinic acid (DMSA) and the association of L-arginine and DMSA on tissue lead mobilization and blood pressure level in plumbism. Braz J Med Biol Res 34: 1341-1346, 2001.
49. Markovac J, Goldstein GW. Picomolar concentrations of lead stimulate brain protein kinase C. Nature 334: 71-73, 1988.
50. Marques M, Millás I, Jiménez A, García-Colis E, Rodriguez-Feo JA, Velasco S, Barrientos A, Casado S, Lopez-Farre A. Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced HTN in rats. J Am Soc Nephrol 12: 2594-2600, 2001.
51. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 μmol/l (10 μg/dl) and mortality among US adults. Circulation 114: 1388-1394, 2006.
52. Molero L, Carrasco C, Marques M, Vaziri ND, Mateos-Caceres PJ, Casado S, Macaya C, Barrientos A, Lopez-Farre AJ. Involvement of endothelium and endothelin-1 in lead-induced smooth muscle cell dysfunction in rats. Kidney Int 69: 685-690, 2006.
53. Muntner P, Menke A, DeSalvo KB, Rabito FA, Batuman V. Continued decline in blood lead levels among adults in the United States: The National Health and Nutrition Examination Surveys. Arch Intern Med 165: 2155-2161, 2005.
54. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease - a systematic review. Environ Health Perspect 115: 472-482, 2007.
55. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 109: 3196-3201, 2007.
56. Nawrot TS, Thijs L, Hond Den EM, Roels HA, Staessen JA. An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens 16: 123-131, 2002.
57. Ni Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 66: 2329-2336, 2004.
58. Oishi H, Nakashima M, Totoki T, Tomokuni K. Chronic lead exposure may inhibit endothelium-dependent hyperpolarizing factor in rats. J Cardiovasc Pharmacol 28: 558-563, 1996.
59. Piccinini F, Favalli L, Chiari MC. Experimental investigations on the contraction induced by lead in arterial smooth muscle. Toxicology 8: 43-51, 1977.
60. Prentice RC, Kopp SJ. Cardiotoxicity of lead at various perfusate calcium concentrations: functional and metabolic responses of the perfused rat heart. Toxicol Appl Pharmacol 81: 491-501, 1985.
61. Purdy RE, Smith JR, Ding Y, Oveisi F, Varizi ND, Gonick HC. Lead-induced HTN is not associated with altered vascular reactivity in vitro. Am J Hypertens 10: 997-1003, 1997.
62. Rabinowitz MB. Toxicokinetics of bone lead. Environ Health Perspect 91: 33, 1991.
63. Ramesh GT, Manna SK, Aggarwal BB, Jadhav AL. Lead exposure activates nuclear factor κB, activator protein-1, c-Jun N-terminal kinase and caspases in the rat brain. Toxicol Lett 123: 195-207, 2001.
64. Revis NW, Zinsmeister AR, Bull R. Atherosclerosis and HTN induction by lead and cadmium ions: an effect prevented by calcium ion. Proc Natl Acad Sci USA 78: 6494-6498, 1981.
65. 2+-binding proteins. Biochem Pharmacol 35: 1331-1335, 1986.
66. Rodríguez-Iturbe B, Sindhu RK, Quiroz Y, Vaziri ND. Chronic exposure to low doses of lead results in renal infiltration of immune cells, NF-κB activation, and overexpression of tubulointerstitial angiotensin II. Antioxid Redox Signaling 7: 1269-1274, 2005.
67. Rodríguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive HTN: all for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004.
68. Schober SE, Mirel LB, Graubard BI, Brody DJ, Flegal KM. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III Mortality Study. Environ Health Perspect 114: 1538-1541, 2006.
69. Schwartz J. Lead, blood pressure, and cardiovascular disease in men. Arch Environ Health 50: 31-37, 1995.
70. Schwartz J. Lead, blood pressure, and cardiovascular disease in men and women. Environ Health Perspect 91: 71-75, 1991.
71. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41: 15S-22S, 2003.
72. Sharifi AM, Darabi R, Akbarloo N, Larijani B, Khoshbaten A. Investigation of circulatory and tissue ACE activity during development of lead-induced HTN. Toxicol Lett 153: 233-238, 2004.
73. Sharp DS, Becker CE, Smith AH. Chronic low-level lead exposure. Its role in the pathogenesis of HTN. Med Toxicol 2: 210-232, 1987.
74. Shelkovnikov SA, Gonick HC. Influence of lead on rat thoracic aorta contraction and relaxation. Am J Hypertens 14: 873-878, 2001.
75. Simons TJB. Lead transport and binding by human erythrocytes in vitro. Pflügers Arch 423: 307-313, 1993.
76. Simons TJB. Lead-calcium interactions in cellular lead toxicity. Neurotoxicology 14: 77-86, 1993.
77. Staessen JA, Bulpitt CJ, Fagard R, Lauwerys RR, Roels H, Thijs L, Amery A. HTN caused by low-level lead exposure: myth or fact? J Cardiovasc Risk 1: 87-97, 1994.
78. Staessen JA, Roels H, Lauwerys RR, Amery A. Low-level lead exposure and blood pressure. J Hum Hypertens 9: 303-328, 1995.
79. Tsao DA, Yu HS, Cheng JT, Ho CK, Chang HR. The change of β-adrenergic system in lead-induced HTN. Toxicol Appl Pharmacol 164: 127-133, 2000.
80. Ueda D, Kishimoto T, Dekio S, Tada M. Inhibitory effect of lead on tube formation by cultured human vascular endothelial cells. Hum Cell 10: 283-291, 1997.
81. 2+-independent contraction in rat aortic rings. Pharmacol Toxicol 89: 177-182, 2001.
82. Vander AJ. Chronic effects of lead on the renin-angiotensin system. Environ Health Perspect 78: 77-83, 1988.
83. Vaziri ND. Pathogenesis of lead-induced HTN: role of oxidative stress. J Hypertens Suppl 20: S15-S20, 2002.
84. Vaziri N, Ding Y. Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide. Hypertension 37: 223-226, 2001.
85. Vaziri ND, Ding Y, Ni Z. Nitric oxide synthase expression in the course of lead-induced HTN. Hypertension 34: 558-562, 1999.
86. Vaziri ND, Ding Y, Ni Z. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced HTN: reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 298: 679-685, 2001.
87. Vaziri ND, Ding Y, Ni Z, Barton CH. Bradykinin down-regulates, whereas arginine analogs upregulate, endothelial nitric-oxide synthase expression in coronary endothelial cells. J Pharmacol Exp Ther 313: 121-126, 2005.
88. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced HTN: effect of lazaroid therapy. Kidney Int 52: 1042-1046, 1997.
89. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation by reactive oxygen species in lead-induced HTN. Kidney Int 56: 1492-1498, 1999.
90. Vaziri ND, Lin CY, Farmand F, Sindhu RK. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced HTN. Kidney Int 63: 186-194. 2003.
91. Vaziri ND, Rodriguez-Itrube B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of HTN. Nat Clin Pract Nephrol 2: 582-593, 2006.
92. Vaziri ND, Sica D. Lead-induced HTN: role of oxidative stress. Curr Hypertens Rep 6: 314-320, 2004.
93. Vaziri ND, Wang XQ. cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 34: 1237-1241, 1999.
94. Watts SW, Chai S, Webb RC. Lead acetate-induced contraction in rabbit mesenteric artery: interaction with calcium and protein kinase C. Toxicology 99: 55-65, 1995.
95. Webb RC, Winquist RJ, Victery W, Vander AJ. In vivo and in vitro effects of lead on vascular reactivity in rats. Am J Physiol Heart Circ Physiol 241: H211-H216, 1981.
96. Yamamoto C, Miyamoto A, Sakamoto M, Kaji T, Kozuka H. Lead perturbs the regulation of spontaneous release of tissue plasminogen activator and plasminogen activator inhibitor-1 from vascular smooth muscle cells and fibroblasts in culture. Toxicology 117: 153-161, 1997.
97. Zhen JH, Lu H, Wang XQ, Vaziri ND, Zhou XJ. Up-regulation of endothelial and inducible nitric oxide synthase by reactive oxygen species. Am J Hypertens 21: 28-34, 2008.